Jeffrey A. Gilreath

1.1k total citations
34 papers, 725 citations indexed

About

Jeffrey A. Gilreath is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Jeffrey A. Gilreath has authored 34 papers receiving a total of 725 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 14 papers in Genetics and 7 papers in Oncology. Recurrent topics in Jeffrey A. Gilreath's work include Erythropoietin and Anemia Treatment (11 papers), Iron Metabolism and Disorders (10 papers) and Hemoglobinopathies and Related Disorders (9 papers). Jeffrey A. Gilreath is often cited by papers focused on Erythropoietin and Anemia Treatment (11 papers), Iron Metabolism and Disorders (10 papers) and Hemoglobinopathies and Related Disorders (9 papers). Jeffrey A. Gilreath collaborates with scholars based in United States, France and Georgia. Jeffrey A. Gilreath's co-authors include George M. Rodgers, David D. Stenehjem, Joseph Bubalo, Mimi Lo, Charles S. Cleeland, Gordana Vlahovic, Morey A. Blinder, Eric H. Kraut, Peter F. Coccia and Rowena Schwartz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Jeffrey A. Gilreath

29 papers receiving 702 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey A. Gilreath United States 12 378 192 173 89 86 34 725
David H. Regan United States 7 774 2.0× 252 1.3× 263 1.5× 97 1.1× 53 0.6× 9 991
Cyrus C. Hsia Canada 11 258 0.7× 54 0.3× 118 0.7× 50 0.6× 69 0.8× 83 541
Charis Matsouka Greece 14 623 1.6× 230 1.2× 233 1.3× 32 0.4× 334 3.9× 37 932
Ronald Bukowski United States 10 481 1.3× 359 1.9× 132 0.8× 45 0.5× 133 1.5× 23 999
Mansour Alfayez United States 15 410 1.1× 161 0.8× 158 0.9× 23 0.3× 233 2.7× 54 775
Jonas Wallvik Sweden 17 445 1.2× 57 0.3× 215 1.2× 45 0.5× 122 1.4× 32 871
Brenda Sarokhan United States 10 953 2.5× 286 1.5× 254 1.5× 95 1.1× 35 0.4× 11 1.2k
EE Morse United States 15 217 0.6× 181 0.9× 114 0.7× 67 0.8× 96 1.1× 46 695
Michael Hedenus Sweden 18 1.3k 3.3× 359 1.9× 532 3.1× 113 1.3× 101 1.2× 42 1.6k
Benedikt Schaefer Austria 19 481 1.3× 441 2.3× 301 1.7× 40 0.4× 326 3.8× 44 1.3k

Countries citing papers authored by Jeffrey A. Gilreath

Since Specialization
Citations

This map shows the geographic impact of Jeffrey A. Gilreath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey A. Gilreath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey A. Gilreath more than expected).

Fields of papers citing papers by Jeffrey A. Gilreath

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey A. Gilreath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey A. Gilreath. The network helps show where Jeffrey A. Gilreath may publish in the future.

Co-authorship network of co-authors of Jeffrey A. Gilreath

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey A. Gilreath. A scholar is included among the top collaborators of Jeffrey A. Gilreath based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey A. Gilreath. Jeffrey A. Gilreath is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Benefield, Russell J, et al.. (2025). Platelet response following dexamethasone in obese vs nonobese patients with primary, acute immune-mediated thrombocytopenia. Research and Practice in Thrombosis and Haemostasis. 9(3). 102844–102844.
2.
Trabert, Britton, Lindsay J. Collin, Morgan M. Millar, et al.. (2025). Tattooing and risk of melanoma: a population-based case-control study in Utah. JNCI Journal of the National Cancer Institute. 117(12). 2495–2504. 1 indexed citations
3.
Rodgers, George M. & Jeffrey A. Gilreath. (2025). Reply to: Concerns on Potential Risk of Roxadustat in Promoting Tumor Progression: Double-Edged Sword of Hypoxia-Inducible Factor-1α Activation. Journal of Clinical Oncology. 43(10). 1267–1268. 1 indexed citations
4.
Atallah, Ehab, Michael S. Broder, Onyee Chan, et al.. (2024). U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML). Blood. 144(Supplement 1). 5052–5052.
5.
Trabert, Britton, David Kriebel, Morgan M. Millar, et al.. (2024). Tattoos and Risk of Hematologic Cancer: A Population‐Based Case–Control Study in Utah. Cancer Medicine. 13(20). e70260–e70260. 4 indexed citations
6.
Rodgers, George M., et al.. (2023). Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura. Journal of Blood Medicine. Volume 14. 209–211.
7.
Stenehjem, David D., et al.. (2022). Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia. Journal of Oncology Pharmacy Practice. 28(4). 916–923. 5 indexed citations
8.
9.
Makharadze, Tamta, Ralph V. Boccia, Anna Julia Krupa, et al.. (2021). Efficacy and safety of ferric carboxymaltose infusion in reducing anemia in patients receiving chemotherapy for nonmyeloid malignancies: A randomized, placebo‐controlled study (IRON‐CLAD). American Journal of Hematology. 96(12). 1639–1646. 15 indexed citations
10.
Lim, Ming Y. & Jeffrey A. Gilreath. (2020). Periprocedural use of avatrombopag for neurosurgical interventions: a strategy to avoid platelet utilization. Blood Advances. 4(18). 4438–4441. 3 indexed citations
11.
Rodgers, George M. & Jeffrey A. Gilreath. (2019). The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy. Acta Haematologica. 142(1). 13–20. 34 indexed citations
12.
13.
Gilreath, Jeffrey A., et al.. (2016). Proposed Algorithm for Managing Ibrutinib-Related Atrial Fibrillation.. PubMed. 30(11). 970–4, 980. 25 indexed citations
14.
McPherson, Jordan P., et al.. (2016). Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 36(2). e8–e11. 1 indexed citations
15.
Rodgers, George M., Jeffrey A. Gilreath, Morey A. Blinder, et al.. (2014). NCCN Guidelines Version 3.2014 Panel Members Cancer- and Chemotherapy-Induced Anemia. 3 indexed citations
16.
17.
Rodgers, George M., Pamela S. Becker, Morey A. Blinder, et al.. (2012). Cancer- and Chemotherapy-Induced Anemia. Journal of the National Comprehensive Cancer Network. 10(5). 628–653. 171 indexed citations
18.
Gilreath, Jeffrey A., David D. Stenehjem, & George M. Rodgers. (2012). Total Dose Iron Dextran Infusion in Cancer Patients: Is it SaFe2+?. Journal of the National Comprehensive Cancer Network. 10(5). 669–676. 12 indexed citations
19.
Mortimer, Joanne, Andrea M. Barsevick, Charles L. Bennett, et al.. (2010). Studying Cancer-Related Fatigue: Report of the NCCN Scientific Research Committee. Journal of the National Comprehensive Cancer Network. 8(12). 1331–1339. 56 indexed citations
20.
Gilreath, Jeffrey A., et al.. (2008). Establishing an Anemia Clinic for Optimal Erythropoietic-Stimulating Agent Use in Hematology-Oncology Patients. Journal of the National Comprehensive Cancer Network. 6(6). 577–584. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David H. Regan Breakdown of academic impact, for papers by Cyrus C. Hsia Breakdown of academic impact, for papers by Charis Matsouka Breakdown of academic impact, for papers by Ronald Bukowski Breakdown of academic impact, for papers by Mansour Alfayez Breakdown of academic impact, for papers by Jonas Wallvik Breakdown of academic impact, for papers by Brenda Sarokhan Breakdown of academic impact, for papers by EE Morse Breakdown of academic impact, for papers by Michael Hedenus Breakdown of academic impact, for papers by Benedikt Schaefer
Rankless by CCL
2026